GPR50, significantly upregulated in hepatocellular carcinoma (HCC) patients and the CBRH-7919 cell line, promotes HCC progression by enhancing cell proliferation, migration, and autophagy, mediated through interactions with CCT6A and PGK1, suggesting GPR50 as a potential therapeutic target for HCC. Here, CCT6A is linked to hepatocellular carcinoma.